Data Sheet (Cat.No.TMAY-00194P)

TargetMol

Anti-BAFF/TNFSF13B Antibody-PE (9F115)

Product Details

Ig Type:	Rabbit IgG
Reactivity:	Human
Conjugation:	PE
Clone:	9F115
Purification:	Protein A

Applications

Verified Activity:	Flow cytometric analysis of Human BAFF(CD257) expression on U937 cells. Cells were stained with PE-conjugated anti-Human BAFF(CD257). The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells.
Application:	FCM
Recommended	10 µl/Test, 0.1 mg/ml

Properties

Stability & Storage:	Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight.
Shipping:	Shipping with blue ice.

Antigen Details

Immunogen:	Recombinant Protein: Human BLyS/TNFSF13B Protein (TMPY-02775)
Antigen Species:	Human
Synonyms:	TALL-1;TALL1;DTL;TNFSF20;tumor necrosis factor (ligand) superfamily, member 13b;BAFF;ZTNF4;THANK;CD257;BLYS

Research Background

B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is a single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors are a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). BLyS is an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481